Biogen Abandons Aducanumab, Pivots Focus to Lecanemab for Al

Aducanumab’s accelerated approval was controversial and insurance coverage was limited of the expensive therapy.

Related Keywords

New York , United States , American , Eli Lilly , Aducanumab Aduhelm , Institute For Clinical , New York Times , Coverage Determination , American Journal , Alzheimer Disease , Aducanumab , Lecanumab ,